{
    "clinical_study": {
        "@rank": "159608", 
        "arm_group": [
            {
                "arm_group_label": "aspirin", 
                "arm_group_type": "Active Comparator", 
                "description": "Aspirin dosage 100 mg/day"
            }, 
            {
                "arm_group_label": "standard medication", 
                "arm_group_type": "No Intervention", 
                "description": "the patients will continue with standard medication"
            }
        ], 
        "brief_summary": {
            "textblock": "The objective of the study is to examine whether the use of low-dose aspirin (75-100 mg /\n      day) reduces the risk of cardiovascular disease in patients with chronic kidney disease\n      (stage 3 or 4)."
        }, 
        "brief_title": "Primary Cardiovascular Risk Prevention With Aspirin in Chronic Kidney Disease Patients", 
        "completion_date": {
            "#text": "May 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Chronic Kidney Disease Stage 4", 
            "Chronic Kidney Disease Stage 3"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Kidney Diseases", 
                "Renal Insufficiency, Chronic", 
                "Kidney Failure, Chronic"
            ]
        }, 
        "detailed_description": {
            "textblock": "Hypothesis: The low-dose aspirin reduces cardiovascular risk in patients with chronic kidney\n      disease without increasing the risk of bleeding"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  sign informed consent\n\n          -  males 45-79 years or females 55-79 years. -Stage 3 or 4 CKD (estimated GFR by MDRD\n             abbreviated, between 15 and 60 ml / min/1.73 m2) -\n\n        Exclusion Criteria:\n\n          -  a previous cardiovascular event: cardiac arrhythmias, cardiac arrest, angina or acute\n             myocardial infarction, stroke, carotid stenosis of more than 50%, peripheral vascular\n             arteriopathy documented\n\n          -  hospitalization for any cause in the last three months prior to inclusion in the\n             study allergy of acetyl-salicylic acid\n\n          -  coagulopathy from any cause\n\n          -  thrombocytopenia <150,000 platelets\n\n          -  liver disease from any cause\n\n          -  Infection by hepatitis B virus, hepatitis C or HIV\n\n          -  immunosuppressive treatment within 12 weeks before inclusion in the study\n\n          -  Major bleeding events including gastrointestinal bleeding and brain hemorrhage.\n\n          -  hemoglobinopathies (eg sickle cell disease or thalassemia of any kind)\n\n          -  active malignancy (except non-melanoma skin cancer). May be included in the study\n             patients with malignant neoplasia who have remained disease-free for at least the\n             previous 5 years.\n\n          -  uncontrolled inflammatory disease or symptomatic (eg rheumatoid arthritis, lupus,\n             Chrom disease or bowel inflammatory disease)\n\n          -  hemolysis\n\n          -  treatment with oral anticoagulation and / or antiplatelet therapy prior.\n\n          -  poorly controlled hypertension (> 160/90 mm \u200b\u200bHg) -pregnancy or breast-\n\n          -  women of childbearing potential not using effective contraception."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "79 Years", 
            "minimum_age": "45 Years"
        }, 
        "enrollment": {
            "#text": "97", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 17, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01709994", 
            "org_study_id": "MG001"
        }, 
        "intervention": {
            "arm_group_label": "aspirin", 
            "description": "100 mg/day of aspirin", 
            "intervention_name": "Aspirin", 
            "intervention_type": "Drug", 
            "other_name": "ACETILSALYCILIC ACID"
        }, 
        "intervention_browse": {
            "mesh_term": "Aspirin"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "cardiovascular events", 
            "chronic kidney disease", 
            "bleedings", 
            "progression", 
            "antiinflammatory effects"
        ], 
        "lastchanged_date": "October 17, 2012", 
        "location": {
            "contact": {
                "email": "marian.goicoechea@gmail.com", 
                "last_name": "MARIAN GOICOECHEA, MD, PhD", 
                "phone": "0034915868319"
            }, 
            "facility": {
                "address": {
                    "city": "Madrid", 
                    "country": "Spain", 
                    "zip": "28007"
                }, 
                "name": "Hospital General Universitario Gregorio Mara\u00f1on"
            }, 
            "investigator": {
                "last_name": "MARIAN GOICOECHEA, MD, PhD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Spain"
        }, 
        "number_of_arms": "2", 
        "official_title": "Effect of Aspirin in Primary Prevention of Cardiovascular Risk in Patients With Chronic Kidney Disease (AASER Study)", 
        "other_outcome": {
            "description": "to Analyze the progression of CKD", 
            "measure": "progression of chronic kidney disease", 
            "safety_issue": "No", 
            "time_frame": "five years"
        }, 
        "overall_contact": {
            "email": "jluno.hgugm@salud.madrid.org", 
            "last_name": "JOSE LU\u00d1O, MD, PHD", 
            "phone": "0034915868319"
        }, 
        "overall_official": {
            "affiliation": "Hospital General Universitario Gregorio Mara\u00f1on", 
            "last_name": "JOSE LU\u00d1O, MD, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "Spain: Ethics Committee", 
                "Spain: Spanish Agency of Medicines"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "May 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "To assess the benefit of treatment with low-dose aspirin in the primary prevention of cardiovascular events (incidence of the composite endpoint: death, acute coronary syndrome, stroke or nonfatal acute peripheral arteriopathy disease) in patients with chronic kidney disease who are not in dialysis or renal transplant.", 
            "measure": "Cardiovascular events", 
            "safety_issue": "No", 
            "time_frame": "five years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01709994"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Fundaci\u00f3n de Ayuda a la Investigaci\u00f3n sobre la Hipertensi\u00f3n, Riesgo Cardiovascular y Enfermedades Renales", 
            "investigator_full_name": "Jose Lu\u00f1o Fernandez", 
            "investigator_title": "Headmaster of Nephrology Department", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "-Evaluate the incidence of major bleeding requiring hospitalization", 
                "measure": "Major bleeding", 
                "safety_issue": "Yes", 
                "time_frame": "five years"
            }, 
            {
                "description": "-to analyze the antiinflammatory effect of aspirin in patients with chronic kidney disease", 
                "measure": "antiinflammatory effects of aspirin", 
                "safety_issue": "No", 
                "time_frame": "five years"
            }
        ], 
        "source": "Fundaci\u00f3n de Ayuda a la Investigaci\u00f3n sobre la Hipertensi\u00f3n, Riesgo Cardiovascular y Enfermedades Renales", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Fundaci\u00f3n de Ayuda a la Investigaci\u00f3n sobre la Hipertensi\u00f3n, Riesgo Cardiovascular y Enfermedades Renales", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2010", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "October 2012"
    }
}